I-Mydecine Innovations Group Files Prospectus Supplement, Imemezela Ukuvala Ngaphansi Kwezivumelwano Zokubhalisa Kokwabelana

VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) - I-Mydecine Innovations Group Inc. (“Mydecine” noma “Inkampani”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) inkampani ye-biotechnology enjiniyela igagasi elilandelayo lemithi emisha kanye nezinqubo zokwelapha ukubhekana ngqo nempilo yengqondo ngokugcizelelwa okuthile kokulutheka kanye ne-PTSD, iyajabula ukumemezela ukuthi, maqondana nalokhu: (i) Isivumelwano Sokubhalisa Esivamile Esimenyezelwe ngaphambilini (the “I-Opensky Isivumelwano Sokubhalisa”) ne-OpenSky Opportunities Fund Ltd. (“I-Opensky”) yamhla ziyi-10 kuNdasa wezi-2023; kanye (ii) Nesivumelwano Sokubhalisela Isabelo Esivamile sangomhla zingama-25 kuMfumfu 2023 (i-“Isivumelwano Sokubhalisa Esizimele”, futhi ngokuhlanganyela neSivumelwano Sokubhalisa se-Opensky, “Izivumelwano zokubhalisa”) phakathi kweNkampani nomtshali zimali wobude bezingalo (“I-Standalone Investor” futhi ngokuhlanganyela ne-Opensky, i-“Abatshalizimali”), Inkampani ifake isengezo seshelufu se-prospectus (i-“Isengezo se-Prospectus”) ku-Final Short Form Base Base Shelf Prospectus yeNkampani yesifundazwe sase-Quebec kanye ne-Final Short Form Base Shelf Prospectus Echitshiyelwe futhi Yashiwo Kabusha yesifundazwe ngasinye sase-Canada, yamhla zingama-28 kuJanuwari 2022 (ndawonye, ​​“I-Shelf Prospectus").